FREE Daily Stock Alerts From Stock-PR.com
Celestica Inc. (NYSE:CLS), a global leader in the delivery of end-to-end product lifecycle solutions, announced that it has completed its previously announced acquisition of the semiconductor equipment contract manufacturing operations of Brooks Automation. The operations, based in Portland, Oregon and Wuxi, China, specialize in manufacturing complex mechanical equipment and providing systems integration services for some of the world's largest semiconductor equipment manufacturers.
Celestica is dedicated to delivering end-to-end product lifecycle solutions to drive our customers' success. For further information on Celestica, visit its website at www.celestica.com
Power3 Medical Products, Inc. (OTC:PWRM)
Alzheimer's disease causes brain changes that gradually get worse. It's the most common cause of dementia - a group of brain disorders that cause progressive loss of intellectual and social skills, severe enough to interfere with day-to-day life. In Alzheimer's disease, brain cells degenerate and die, causing a steady decline in memory and mental function.
The first symptoms of Alzheimer's disease you may notice are increasing forgetfulness and mild confusion. Over time, the disease has a growing impact on your memory, your ability to speak and write coherently, and your judgment and problem solving. If you have Alzheimer's, you may be the first to notice that you're having unusual difficulty remembering things and organizing your thoughts. Or you may not recognize that anything is wrong, even when changes are noticeable to your family members, close friends or co-workers.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical Products, Inc. applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical Products, Inc. has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Power3 Medical Products, Inc uses the NuroPro Blood Test as a diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases would allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
For more information, please visit the website: http://www.power3medical.com
US Airways Group, Inc. (NYSE:LCC) and Aegean Airlines customers will soon enjoy greater travel options between Greece and the U.S. thanks to a new bilateral codeshare agreement announced between the two Star Alliance partners. The agreement is subject to both U.S. Department of Transportation (DOT) and Greek government approval. US Airways customers will have access to Athens, the political and cultural capital of Greece, as well as Thessolaniki, Greece, via Aegean Airlines service from London Heathrow, Munich, Germany and Rome. Customers will also have the chance to visit the mythical Greek Islands of Crete, Mykonos, Santorini, Kos, and Rhodes as well as Larnaca, Cyprus, through Aegean Airlines' hub in Athens.
US Airways Group, Inc., through its subsidiaries, provides air transportation for passengers and cargo. It offers scheduled passenger service on approximately 3,200 flights daily to 200 communities in the United States, Canada, Mexico, Europe, the Middle East, the Caribbean, and Central and South America.
Renren Inc. (NYSE:RENN) announced its unaudited financial results for the first quarter ended March 31, 2011. Total net revenues were US$20.6 million, a 46.6% increase from the corresponding period in 2010. Online advertising revenues were US$8.1 million, a 100.5% increase from the corresponding period in 2010. Gross profit was US$16.5 million, a 57.6% increase from the corresponding period in 2010. Net loss was US$2.6 million, a 78.5% decrease from the corresponding period in 2010. Adjusted (1) net loss was US$1.1 million, compared to US$0.6 million adjusted net income in the corresponding period in 2010.
Renren Inc. operates a social networking Internet platform in China. Its platform enables users to connect and communicate with each other; share information and user-generated content; play online games; listen to music; and shop for deals.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup